Researchers successfully used a noninvasive broadband optical spectroscopy (BOS) device to detect necrotizing enterocolitis (NEC) early in premature infants.
Key Details
- 1BOS is a handheld device that measures reflected infrared light from the intestines to detect early NEC.
- 2The technology distinguishes NEC from healthy tissue within two minutes at the bedside.
- 3First-in-human study tested BOS on 96 premature infants younger than 36 weeks gestation.
- 4BOS produced safe, feasible, and detectable signal changes in infants with NEC.
- 5BOS may identify NEC before it appears on x-ray; prior x-ray is the current standard diagnostic tool.
Why It Matters
BOS could allow bedside, early, radiation-free detection of NEC—a life-threatening disease—enabling earlier treatment and potentially improving outcomes in neonates. The move toward new optical imaging modalities may supplement or even precede conventional radiology tools like x-ray in this clinical scenario.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.